UNC researcher presents additional results from groundbreaking genome editing clinical trial
Interim results presented by UNC’s Joseph Muenzer, MD, PhD, provide preliminary evidence that in vivo genome editing occurred in a clinical trial testing a treatment for Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed